Ellansé S, M, L Complication Differences: The Cost of Choosing the Wrong Formulation
Ellanse Formulation Choice: An Underestimated Risk Factor
Ellanse is a collagen-stimulating filler built around polycaprolactone (PCL) microspheres. Its unique feature is offering four formulations — S, M, L, and E — each corresponding to a different duration of effect. This multi-formulation design gives practitioners flexibility, but it also introduces a commonly overlooked issue: choosing the wrong formulation can significantly increase complication risk and management difficulty.
In clinical practice, I have managed a substantial number of Ellanse complication cases and observed a clear trend: complications from longer-lasting formulations (L and E) are consistently more challenging to resolve than those from shorter-acting ones (S and M).
Key Insight: "The longer it lasts, the better" is many patients' instinct, but with collagen stimulators, longer duration means PCL (Polycaprolactone (Ellansé) — longer-lasting collagen stimulator) microspheres remain in tissue longer, the body interacts with them longer, and potential risks increase accordingly.
Fundamental Differences Between the Four Formulations
PCL Microsphere Characteristics
| Formulation | Duration | PCL Content | Microsphere Properties | Collagen Stimulation Period |
|---|---|---|---|---|
| Ellansé S | ~1 year | Lowest | Smaller, faster degradation | ~6–12 months |
| Ellansé M | ~2 years | Moderate | Medium size | ~12–18 months |
| Ellansé L | ~3 years | Higher | Larger, slower degradation | ~18–30 months |
| Ellansé E | ~4 years | Highest | Largest, slowest degradation | ~24–36 months |
Recommended Use Versus Clinical Reality
| Formulation | Manufacturer Recommendation | Clinical Reality |
|---|---|---|
| S | First-time users, conservative approach | Used relatively less (shorter duration) |
| M | Most commonly recommended | Most widely used clinically |
| L | Patients seeking long-term results | Heavily used in some markets |
| E | Special needs (not available in some markets) | Highest complication risk |
How Formulation Affects Complications
Nodule Formation Risk
The longer PCL microspheres remain in tissue, the greater the chance of nodule formation:
| Factor | S/M Types | L/E Types |
|---|---|---|
| PCL retention time | Shorter (1–2 years) | Longer (3–4+ years) |
| Capsule development | Thinner | Potentially thicker and more mature |
| Collagen overgrowth risk | Lower | Higher |
| Palpable nodule incidence | Lower | Higher |
| Delayed inflammatory reaction | Less common | More common |
Extraction Difficulty
When Ellanse removal is needed, formulation directly affects surgical complexity:
| Extraction Factor | S | M | L | E |
|---|---|---|---|---|
| Residual PCL volume | Low | Moderate | High | Highest |
| Capsule thickness | Thin | Moderate | Thick | Thickest |
| Tissue entanglement | Low | Moderate | High | Highest |
| Single-session completion rate | High | High | Moderate | Lower |
| Post-extraction tissue recovery | Fast | Moderate | Slow | Slowest |
Key Insight: When Ellanse L or E develops complications, management is substantially more difficult than with S or M. This does not mean longer formulations are inherently bad — it means the trade-offs must be fully understood before making a choice.
Typical Complication Scenarios by Formulation
S Type: The Most Forgiving Choice
S type has the lowest PCL content and fastest degradation, making it the lowest-risk formulation:
- Nodule formation is rare and usually small
- Even if problems arise, significant improvement typically occurs within 12–18 months
- If extraction is needed, the thin capsule makes removal relatively straightforward
M Type: The Most Common Balanced Choice
M type is the most widely used formulation, with intermediate complication characteristics:
- Nodules may appear 6–12 months post-injection
- Steroid injections may help with early nodules
- Extraction is usually achievable in a single session
L Type: Risk Begins to Escalate
L type's increased PCL content and duration bring elevated management challenges:
- Nodule formation risk is higher than M type
- Thicker capsules reduce steroid and 5-FU penetration
- Extraction may require more refined ultrasound guidance
- Some cases may need staged extraction
E Type: Highest Risk
E type has the longest duration and highest PCL content, with the greatest complication risk and management difficulty:
- Highest nodule formation risk
- Capsules may be very thick and mature
- Medical treatment is usually of limited effect
- Extraction surgery is most complex
- Multiple sessions may be necessary
The Critical Role of Ultrasound Across Formulations
Ultrasound Appearance by Formulation
| Formulation | Ultrasound Appearance | Clinical Significance |
|---|---|---|
| S residual | Small hypoechoic area, thin capsule | Relatively easy to locate and extract |
| M residual | Moderate hypoechoic area, visible capsule line | Standard extraction procedure |
| L residual | Larger hypoechoic area, prominent capsule | Careful extraction path planning needed |
| E residual | Extensive hypoechoic area, thick septated capsule | May require staged management |
Formulation-Specific Extraction Strategy
S/M Type Strategy
- Typically achievable through a single pinhole
- Direct extraction after ultrasound localization
- Single-session completion usually possible
L/E Type Strategy
- May require multiple entry points
- Capsule fragmentation before stepwise extraction
- Staged approach may be safer
- More intensive post-procedure ultrasound follow-up required
Factors to Consider Before Choosing a Formulation
For Patients
| Consideration | Recommendation |
|---|---|
| First time using collagen stimulators | Start with S or M |
| History of filler complications | Avoid L and E |
| Duration expectations | Balance expectations with risk |
| Tolerance for uncertainty | Conservative patients should choose shorter formulations |
| Willingness for follow-up visits | Longer formulations require more diligent monitoring |
For Practitioners
| Consideration | Recommendation |
|---|---|
| Injection precision | L/E types demand higher technical standards |
| Complication management capability | Should have ultrasound-guided extraction capability |
| Patient selection | Avoid longer formulations in high-risk patients |
| Follow-up scheduling | Longer formulations require extended monitoring |
Already Injected a Long-Acting Formulation?
If you have had Ellanse L or E injected and are experiencing nodules, asymmetry, or other problems, there is no need to panic. The important step is seeking professional evaluation early:
- Ultrasound assessment: Confirm PCL residual location, extent, and capsule condition
- Conservative treatment trial: For early inflammatory nodules, steroids or 5-FU may be attempted first
- Minimally invasive extraction: When medical treatment fails, ultrasound-guided extraction is the definitive solution
For more on Ellanse removal, see Can Ellanse Be Removed?
Further reading:
- Collagen Stimulator Nodules: What to Do When 5-FU Fails
- Minimally Invasive Filler Lump Extraction Technique
About the Author
Dr. Ta-Ju Liu
- Current Position: Director, Liusmed Clinic
- Specialties: Minimally invasive surgery, filler complication repair, ultrasound-guided extraction
- Experience: 15+ years of clinical minimally invasive surgery; over 10,000 successful cases
- Philosophy: "Ellanse formulation choice is not just about how long the results last — it is about how difficult complications will be to manage if they arise. Before deciding, make sure you understand the complete risk picture."
Related Services
Specialties
Credentials
- Kaohsiung Medical University, School of Medicine
- Attending Physician, Dermatology, Kaohsiung Chang Gung Memorial Hospital
- Attending Physician, Aesthetic Center, Kaohsiung Chang Gung Memorial Hospital
- Visiting Physician, Dermatology, Xiamen Chang Gung Hospital
- Visiting Physician, Aesthetic Center, Xiamen Chang Gung Hospital
"For every surgery, I strive to achieve the best outcome through the smallest incision and finest technique. Minimally invasive surgery is not just a technique — it's a commitment of respect to every patient."
Recovery from filler complications needs peer support too
Want to learn more?
Schedule a consultation for professional evaluation and advice